呋塞米预防新发产后高血压:一项随机安慰剂对照试验(LAPP试验)
在这项随机三盲安慰剂对照试验中,82名无产前高血压诊断但存在新发产后高血压高风险的产后患者被随机分配接受5天口服呋塞米20mg每日一次或安慰剂。结果显示,呋塞米组出院前或启动降压治疗前24小时平均动脉压为88.9±7.4 mmHg,安慰剂组为86.8±7.1 mmHg,绝对差异2.1 mmHg(95%CI -1.2至5.3),无显著差异。作者认为呋塞米未能降低该平均动脉压的证据不足。
要点
- 在高风险产后患者中,呋塞米组与安慰剂组出院前24小时平均动脉压无显著差异。
- 79名评估次要结局的参与者中,10%(n=8)发生新发产后高血压,9%(n=7)启动降压治疗,组间无显著差异。
- 新发产后高血压在高风险患者中常见,需密切监测严重高血压及其他母体并发症。
核心结论
- 与安慰剂相比,呋塞米降低出院前(或启动降压药物前)24小时平均动脉压的证据不足。
- 新发产后高血压在高风险患者中常见,需密切监测严重高血压及其他母体并发症。
研究设计与样本
- 2021年10月至2022年4月在一所大学附属三级医疗中心进行的随机三盲安慰剂对照临床试验。
- 共纳入82名产后患者,均无产前慢性高血压或妊娠期高血压疾病诊断,但基于预设风险因素算法为新发产后高血压高风险。
- 参与者按1:1随机分配至5天口服呋塞米20mg每日一次组或外观相同的安慰剂组,于分娩后8小时内开始用药。
- 采用蓝牙远程血压监测和电子问卷随访至产后6周。
- 主要结局为出院前24小时或启动降压治疗前24小时的平均动脉压平均值;研究把握度设定为检测平均动脉压5 mmHg差异(标准差6.4 mmHg),90%把握度,α=0.05,每组需41例。
主要发现
- 主要结局在82名参与者中的80名中评估;两组基线特征相似。
- 呋塞米组出院前(或启动降压治疗前)24小时平均动脉压为88.9±7.4 mmHg,安慰剂组为86.8±7.1 mmHg,绝对差异2.1 mmHg(95%CI -1.2至5.3),无显著差异。
- 在评估次要结局的79名参与者中,10%(n=8)发生新发产后高血压,9%(n=7)启动降压治疗,组间率无显著差异(分别为P=.71和P>.99)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Birthing people with de novo postpartum hypertensive disorders continue to be among the populations at highest risk for severe maternal morbidity. Randomized controlled trials demonstrate a benefit of oral loop diuretics in decreasing postpartum hypertensive morbidity in patients with an antenatal diagnosis of preeclampsia. It is not known whether this same therapy benefits patients at risk for new-onset postpartum hypertension. OBJECTIVE: This study aimed to evaluate whether oral furosemide can reduce the risk for de novo postpartum hypertension among high-risk birthing people by reducing postdelivery blood pressure. STUDY DESIGN: From October 2021 to April 2022, we conducted a randomized triple-masked placebo-controlled clinical trial of individuals at high risk for de novo postpartum hypertension at a single university-based tertiary care medical center. A total of 82 postpartum patients with no antenatal diagnosis of chronic hypertension or a hypertensive disorder of pregnancy who were at high risk for the development of de novo postpartum hypertension based on a prespecified risk factor algorithm were enrolled after childbirth. The participants were randomly assigned in a 1:1 ratio to a 5-day course of 20-mg oral furosemide daily or identical-appearing placebo starting within 8 hours of delivery. Participants were followed for 6 weeks postpartum using Bluetooth-enabled remote blood pressure monitoring and electronic surveys. The primary outcome was mean arterial pressure averaged over the 24 hours before discharge or the 24 hours before antihypertensive therapy initiation. The study was powered to detect a 5 mm Hg difference in average mean arterial pressure (standard deviation, 6.4 mm Hg) with 90% power at an alpha of 0.05, requiring a sample size of 41 per group. Secondary outcomes included the rate of de novo postpartum hypertension, readmission data, other measures of hypertensive and maternal morbidity, breastfeeding data, and drug-related neonatal outcomes. RESULTS: The primary outcome was assessed in 80 of the 82 participants. Baseline characteristics were similar between the groups. There was no significant difference in average mean arterial pressure in the 24 hours before discharge (or antihypertensive initiation) in the furosemide group (88.9±7.4 mm Hg) compared with the placebo group (86.8±7.1 mm Hg; absolute difference, 2.1 mm Hg; 95% confidence interval, -1.2 to 5.3). Of the 79 participants for whom secondary outcomes were assessed, 10% (n=8) developed de novo postpartum hypertension and 9% (n=7) were initiated on antihypertensive therapy. Rates were not significantly different between the groups (P=.71 and P>.99, respectively). CONCLUSION: De novo postpartum hypertension is a common phenomenon among at-risk patients, warranting close monitoring for severe hypertension and other maternal morbidity. There is insufficient evidence to suggest that furosemide reduces average mean arterial pressure in the 24 hours before discharge from the delivery hospitalization (or antihypertensive medication initiation) compared with placebo.
引用
- Emeruwa UN, Azad H, Ona S, et al. Lasix for the prevention of de novo postpartum hypertension: a randomized placebo-controlled trial (LAPP Trial). Am J Obstet Gynecol. 2024. PMID: 38641089. doi:10.1016/j.ajog.2024.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。